Regenerative Xenograft Global Market Report 2025

The regenerative xenograft market size has grown rapidly in recent years. It will grow from $1.26 billion in 2024 to $1.4 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be linked to the increasing prevalence of chronic diseases, a rising global geriatric population, growing incidence of orthopedic, dental, cardiovascular, and soft-tissue conditions, increasing awareness and acceptance of regenerative therapies, and rising demand for minimally invasive surgeries and outpatient procedures.

The regenerative xenograft market size is expected to see rapid growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be driven by expanding investments in healthcare infrastructure, increasing applications of xenografts, rising cases of sports-related injuries, road accidents, and trauma, growing research and development activities and collaborations, and strengthening regulations and reimbursement frameworks. Major trends in the forecast period include the integration of advanced technologies, wider adoption of xenografts in complex surgical procedures, innovations in xenograft materials and biomaterials, expansion of application areas, and ongoing technological advancements.

The rising incidence of orthopedic injuries is expected to drive the growth of the regenerative xenograft market in the coming years. Orthopedic injuries, which involve damage to the musculoskeletal system - such as bones, joints, muscles, tendons, and ligaments - typically include fractures, dislocations, sprains, or tears. The increasing frequency of these injuries is largely due to obesity and excess body weight, which place added mechanical stress on bones and joints, accelerating wear and tear and increasing the risk of fractures and joint degeneration. Regenerative xenografts help address the growing prevalence of orthopedic injuries by offering advanced animal-derived biomaterials that promote bone and joint repair, support tissue regeneration, and restore musculoskeletal function. For example, in November 2024, the Health and Safety Executive (HSE), a UK-based national regulator for workplace health and safety, reported that approximately 543,000 workers suffered from work-related musculoskeletal disorders (MSDs) in 2024, up from 473,000 in 2023. This increase highlights the rising prevalence of orthopedic injuries and the growing demand for regenerative solutions, driving the expansion of the regenerative xenograft market.

Leading companies in the regenerative xenograft market are focusing on technological advancements, such as the development of advanced collagen membranes, to meet the rising demand for reliable bone regeneration, improved implant survival, and optimal tissue integration. These advanced collagen membranes are biocompatible, resorbable materials designed to support bone and soft tissue healing. Compared to traditional non-resorbable membranes, which require secondary surgery for removal, advanced collagen membranes offer superior handling, adaptability, and stability. For example, in October 2025, Geistlich Pharma, a Switzerland-based regenerative biomaterials company, launched Geistlich Bio-Gide Forte, an advanced collagen membrane based on its proven Bio-Gide technology. The new membrane features enhanced strength and stability, unfolds easily, adapts flexibly to defect sites, and can be precisely cut even when hydrated. This innovation facilitates complex clinical procedures and supports faster, more reliable bone and tissue regeneration, improving implant survival rates. Geistlich Bio-Gide Forte is currently available in North America, with a European market launch underway, and is offered in multiple sizes to meet diverse surgical needs.

In November 2024, RTI Surgical, a U.S.-based provider of contract development and manufacturing services (CDMO), acquired Collagen Solutions for an undisclosed amount. This acquisition allows RTI Surgical to expand its portfolio of soft-tissue and xenograft biomaterials by leveraging Collagen Solutions’ expertise in bovine and porcine collagen. This move is aimed at accelerating access to high-growth therapeutic areas such as cardiac, sports medicine, orthopedic, and reconstructive surgery. Collagen Solutions is a US-based company that specializes in engineered medical-grade collagen and xenograft tissue products for original equipment manufacturers (OEMs).

Major companies operating in the regenerative xenograft market are Stryker Corporation, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Dentsply Sirona, Arthrex Inc., Integra LifeSciences Corporation, Nobel Biocare, Organogenesis Holdings Inc., Osstem Implant, MiMedx Group Inc., Vericel Corporation, LifeNet Health, BioTissue Holdings Inc., Geistlich Pharma AG, RTI Surgical Holdings Inc., Tissue Regenix Group plc, Viscus Biologics, Botiss Biomaterials GmbH, Revivicor Inc., Genoss Co. Ltd.

North America was the largest region in the regenerative xenograft market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in regenerative xenograft report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the regenerative xenograft market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The regenerative xenograft market research report is one of a series of new reports that provides regenerative xenograft market statistics, including regenerative xenograft industry global market size, regional shares, competitors with a regenerative xenograft market share, detailed regenerative xenograft market segments, market trends and opportunities, and any further data you may need to thrive in the regenerative xenograft industry. This regenerative xenograft market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A regenerative xenograft is a biological graft sourced from a different species and designed to support and stimulate tissue regeneration in the recipient. It functions as a scaffold that encourages the patient’s own cells to grow, repair, or replace damaged tissues. The primary goal of a regenerative xenograft is to enable natural healing and tissue restoration while eventually integrating into or being replaced by the patient’s own tissue.

The main types of xenografts in regenerative xenograft include bone xenografts, cartilage xenografts, dermal xenografts, dental xenografts, and vascular xenografts. Bone xenografts are regenerative biomaterials obtained from animal bone - typically bovine or porcine - used to facilitate bone repair and regeneration in human orthopedic and dental procedures. These are available in formulations such as powdered form, liquid form, gel form, sheet form, and composite form, and are derived from sources including donor porcine xenografts, bovine xenografts, equine xenografts, and canine xenografts. They are used in applications such as orthopedic surgery, dental surgery, cardiovascular surgery, wound healing, and cosmetic surgery, and serve end users including hospitals, ambulatory surgical centers, specialty clinics, research institutes, and others.

The regenerative xenograft market consists of sales of products such as dermal xenografts for skin repair, bone and dental xenografts for orthopedic and dental reconstruction, cartilage and meniscus xenografts for joint restoration, vascular xenografts for blood vessel replacement, and cardiac xenografts, including heart valves and pericardial tissues. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.